Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Capital Expenditures (2016 - 2020)

Historic Capital Expenditures for Larimar Therapeutics (LRMR) over the last 8 years, with Q4 2020 value amounting to $397000.0.

  • Larimar Therapeutics' Capital Expenditures rose 69400.0% to $397000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $460000.0, marking a year-over-year increase of 45421.69%. This contributed to the annual value of $515000.0 for FY2024, which is 21402.44% up from last year.
  • Per Larimar Therapeutics' latest filing, its Capital Expenditures stood at $397000.0 for Q4 2020, which was up 69400.0% from $5000.0 recorded in Q3 2020.
  • Larimar Therapeutics' Capital Expenditures' 5-year high stood at $400000.0 during Q1 2016, with a 5-year trough of $1000.0 in Q1 2018.
  • In the last 5 years, Larimar Therapeutics' Capital Expenditures had a median value of $23500.0 in 2018 and averaged $85375.0.
  • Per our database at Business Quant, Larimar Therapeutics' Capital Expenditures soared by 138148.15% in 2016 and then tumbled by 9769.23% in 2017.
  • Larimar Therapeutics' Capital Expenditures (Quarter) stood at $260000.0 in 2016, then tumbled by 89.62% to $27000.0 in 2017, then tumbled by 55.56% to $12000.0 in 2018, then surged by 316.67% to $50000.0 in 2019, then surged by 694.0% to $397000.0 in 2020.
  • Its Capital Expenditures stands at $397000.0 for Q4 2020, versus $5000.0 for Q3 2020 and $58000.0 for Q1 2020.